15
total announcements
532531.BO · 15 min delayed
Strides Pharma Science Ltd
Strides Pharma Science Ltd's flagship manufacturing facility in Bengaluru has received the Establishment Inspection Report (EIR) from the USFDA, indicating the successful closure of the inspection with a Voluntary Action Indicated (VAI) outcome.
Strides Pharma Science Ltd
Strides Pharma Science Ltd has announced the voting results of its 35th Annual General Meeting (AGM), where all resolutions were passed with requisite majority. The company has also declared a final dividend for the financial year ended March 31, 2026, and re-appointed a retiring director.
Strides Pharma Science Ltd
Strides Pharma Science Ltd held its 35th Annual General Meeting (AGM) on August 14, 2026, through video conference. The meeting was attended by the company's directors, officials, and representatives of statutory auditors, internal auditors, and secretarial auditors. The AGM Notice, Board's Report, and Auditor's Report for the financial year ended March 31, 2026, were taken as read. The shareholders were informed that the Auditor's Reports did not contain any qualifications, observations, or adverse comments. The statutory registers and other documents were available for electronic inspection. The company's existing ESOP Scheme was implemented in accordance with SEBI Regulations and approved by the shareholders.
Strides Pharma Science Ltd
Strides Pharma Science Ltd reported Q1 FY27 results, with 13% YoY growth in topline, driven by broad-based contributions across its business, and maintained EBITDA margins at 18.2% despite additional operating and freight costs.
Strides Pharma Science Ltd
Strides Pharma Science Ltd has published unaudited financial results for the quarter ended June 30, 2026, as per Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results are available on the company's website and in newspapers.
Strides Pharma Science Ltd
Strides Pharma Science Ltd has made available the audio recording of its earnings call for Q1 FY27, which was held on July 31, 2026, to discuss unaudited financial results for the quarter ended June 30, 2026. The recording is available on the company's website.
Strides Pharma Science Ltd
Strides Pharma Science Ltd has announced its Q1FY27 earnings, with revenue growth of 13% YoY, and EBITDA growth of 5.4% YoY, despite a ₹131m impact on freight and operating costs from geopolitical disruptions. The company has also unlocked ₹1,000m of value through the divestment of its majority stake in Pivot Path, and improved its EcoVadis sustainability score to 68/100, a 19-point increase over last year.
Strides Pharma Science Ltd
Strides Pharma Science Ltd reported Q1FY27 results with revenue at ₹12,654m, a 13% YoY growth, driven by 17% YoY growth in Ex-US Markets. EBITDA grew 5.4% YoY to ₹2,298m, despite a ₹131m impact on operating costs from geopolitical disruptions. The company unlocked ₹1,000m of value through the divestment of its majority stake in Pivot Path, its captive GCC, while retaining meaningful participation in its future growth.
Strides Pharma Science Ltd
Strides Pharma Science Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, as approved by the Board of Directors. The company has released its consolidated and standalone financial results, along with a limited review report from its auditors.
Strides Pharma Science Ltd
Strides Pharma Science Ltd has scheduled an Earnings Call for investors/analysts to discuss its Unaudited Financial Results for the quarter ended June 30, 2026.
Strides Pharma Science Ltd
Strides Pharma Science Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 31/07/2026 to consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Strides Pharma Science Ltd
Strides Pharma Science Ltd has submitted its Business Responsibility and Sustainability Report for FY 2026, as required by SEBI regulations.
Strides Pharma Science Ltd
Strides Pharma Science Ltd has announced its 35th Annual General Meeting (AGM) to be held on August 14, 2026, through Video Conference/ Other Audio-Visual Means (VC/ OAVM). The meeting will consider the adoption of audited financial statements and other business.
Strides Pharma Science Ltd
Strides Pharma Science Ltd has announced its 35th Annual General Meeting (AGM) to be held on August 14, 2026, through video conference. The meeting will consider the audited financial statements for FY 2025-26 and other business items.
Strides Pharma Science Ltd
Strides Pharma Science Ltd is scheduling its 35th Annual General Meeting (AGM) on August 14, 2026, through video conference or other audio-visual means. The meeting will consider the audited financial statements for FY2025-26 and other business.